Republicans have finally produced a detailed plan to repeal and replace the Affordable Care Act, also known as Obamacare. Setting aside politics and viewing the plan neutrally, two things jump out. First, the House Republicans’ plan keeps the basic framework of Obamacare. No wonder some are calling it “Obamacare Lite.”
Donald Trump is starting his first full week as U.S. president. Bearish investors have been out in full force, proclaiming, with high confidence, that it’s time to sell stocks. At the same time, bullish gurus are saying just the opposite. So who’s right? Let’s explore the answer. First, we need
Donald Trump knocked yet another industry in his press conference Wednesday, but this time it wasn’t manufacturers or car makers. It was health care. And shares of U.S. pharmaceutical companies promptly fell, dropping by an average range of about 3% to 5%. “We’ve got to get our drug industry back,”
I can safely say that, from my 35 years in the financial markets, to be consistently successful at investing, one must put prudence over popularity. Human nature as it is, investors often find it difficult to take unpopular actions. My motivation in writing this column is to nudge you
Democrats will fight tooth and nail to save Obamacare, but given the flaws in the plan, they are not likely to succeed. Obamacare in its current form is the walking dead. Trump has said that he will replace Obamacare with something better. In his speeches, Trump outlined certain key points
It is official: India is siding with poor cancer patients over profits for multinational drug giants. The Supreme Court of India has rejected a plea by Swiss pharma giant Novartis that ends the seven-year legal battle to restrict Indian companies from copying blood cancer drug Glivec. Novartis had filed a plea with the Supreme
Obama has been re-elected; “Obamacare” is the law of the land. It doesn’t matter if you agree or disagree with Obamacare, you might as well generate big profits from it. Obamacare has been profitable for us. We bought Amerigroup Corp. AGP at $22.05, and, as of this writing, the stock
This post was published on ZYX Short Sell Change Alert Consider taking profits and exiting LLY trade right here around $43.60. We will provide more details over the weekend.
This post was published on ZYX Short Sell Change Alert Consider taking profits on the last tranche from around $46 right here $43.40- 43.65. THis will leave 20% still held.
This post was published on ZYX Short Sell Change Alert We are repeating that conservative investors should not enter this trade. Even though the trial has failed and there is not enough life left in the patent, the disease evokes such emotion the some will continue to run up the stock.